eligibility_summary
Adults ≥18 with relapsed CD20+ FL grade 1–3a (safety run-in) or relapsed CD20+ DLBCL (both, expansion DLBCL only), ≥1 prior therapy, measurable node (>1.5 cm), adequate blood counts/renal/hepatic function, willing for transfusions, contraception/Revlimid REMS. Exclude prior pola/mosun/tafa±len, recent SCT/CAR‑T or auto‑SCT eligible, transplant history, major comorbidities, active infections (HBV/HCV/HIV/TB/EBV), CNS disease, recent chemo/RT/surgery, ≥grade 2 neuropathy, pregnancy, bleeding/VTE, other trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05615636 is a Phase II, single-arm study in relapsed/refractory B‑cell NHL (FL grade 1–3a, DLBCL) testing four agents: 1) Mosunetuzumab (IV), a CD20×CD3 bispecific T‑cell–engaging antibody that redirects T cells (via CD3) to kill CD20+ B cells. 2) Polatuzumab vedotin (IV), an antibody–drug conjugate targeting CD79b on B cells to deliver MMAE, a microtubule‑disrupting cytotoxin. 3) Tafasitamab (IV), an Fc‑engineered anti‑CD19 monoclonal antibody that enhances ADCC/ADCP against CD19+ B cells. 4) Lenalidomide (oral IMiD) that binds cereblon to degrade Ikaros/Aiolos, boosting T‑ and NK‑cell function and enhancing ADCC. Targets/pathways: CD20, CD79b (BCR component), and CD19 on malignant B cells, CD3 on T cells, cereblon E3 ligase pathway, immune effector activation (T/NK) and tumor microenvironment modulation.